1. Home
  2. ELDN vs SFST Comparison

ELDN vs SFST Comparison

Compare ELDN & SFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELDN
  • SFST
  • Stock Information
  • Founded
  • ELDN 2004
  • SFST 1999
  • Country
  • ELDN United States
  • SFST United States
  • Employees
  • ELDN N/A
  • SFST N/A
  • Industry
  • ELDN Biotechnology: Pharmaceutical Preparations
  • SFST Major Banks
  • Sector
  • ELDN Health Care
  • SFST Finance
  • Exchange
  • ELDN Nasdaq
  • SFST Nasdaq
  • Market Cap
  • ELDN 288.5M
  • SFST 292.1M
  • IPO Year
  • ELDN N/A
  • SFST 1999
  • Fundamental
  • Price
  • ELDN $4.09
  • SFST $37.50
  • Analyst Decision
  • ELDN Strong Buy
  • SFST
  • Analyst Count
  • ELDN 1
  • SFST 0
  • Target Price
  • ELDN $16.00
  • SFST N/A
  • AVG Volume (30 Days)
  • ELDN 520.7K
  • SFST 19.1K
  • Earning Date
  • ELDN 11-12-2024
  • SFST 01-28-2025
  • Dividend Yield
  • ELDN N/A
  • SFST N/A
  • EPS Growth
  • ELDN N/A
  • SFST N/A
  • EPS
  • ELDN N/A
  • SFST 1.73
  • Revenue
  • ELDN N/A
  • SFST $90,166,000.00
  • Revenue This Year
  • ELDN N/A
  • SFST N/A
  • Revenue Next Year
  • ELDN N/A
  • SFST $13.55
  • P/E Ratio
  • ELDN N/A
  • SFST $21.68
  • Revenue Growth
  • ELDN N/A
  • SFST 3.18
  • 52 Week Low
  • ELDN $1.52
  • SFST $24.98
  • 52 Week High
  • ELDN $5.54
  • SFST $45.91
  • Technical
  • Relative Strength Index (RSI)
  • ELDN 47.03
  • SFST 45.98
  • Support Level
  • ELDN $3.68
  • SFST $35.48
  • Resistance Level
  • ELDN $4.19
  • SFST $36.54
  • Average True Range (ATR)
  • ELDN 0.32
  • SFST 1.02
  • MACD
  • ELDN -0.04
  • SFST 0.10
  • Stochastic Oscillator
  • ELDN 31.54
  • SFST 57.63

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

About SFST Southern First Bancshares Inc.

Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the "FDIC"), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.

Share on Social Networks: